NCT06918834View on ClinicalTrials.gov

Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients

PHASE2RecruitingINTERVENTIONAL
Enrollment

236

Participants

Timeline

Start Date

July 24, 2025

Primary Completion Date

April 1, 2028

Study Completion Date

April 1, 2028

Conditions
Myelodysplastic Syndromes
Interventions
OTHER

Immediate HSCT Group

Patients undergo direct allogeneic HSCT.

OTHER

Bridging Therapy Group

"Patients receive one to two cycles of bridging therapy before undergoing allogeneic HSCT.~o Bridging Therapy Regimen: Hypomethylating agents (HMA) alone or HMA-based combination chemotherapy, e.g., azacitidine (AZA) 100 mg/day + venetoclax (VEN) 400 mg/day for 7 days. Targeted therapies (e.g., IDH1 inhibitors) will be used for eligible patients."

Trial Locations (5)

100044

RECRUITING

Peking University People's Hospital, Beijin

450000

RECRUITING

Zhengzhou University First Affiliated Hospital, Zhengzhou

610083

RECRUITING

People's Liberation Army The General Hospital of Western Theater Command, Chengdu

Unknown

RECRUITING

The 960th Hospital of the Joint Service Support Force of the Chinese People's Liberation Army, Jinan

RECRUITING

The Second Hospital of Hebei Medical University, Shijia Zhuang

All Listed Sponsors
lead

Institute of Hematology & Blood Diseases Hospital, China

OTHER

NCT06918834 - Efficacy of Immediate Allogeneic Hematopoietic Stem Cell Transplantation Versus Bridging Therapy Followed by Transplantation in Higher-Risk Myelodysplastic Syndrome Patients | Biotech Hunter | Biotech Hunter